
Quarterly report 2023-Q3
added 11-20-2023
Acer Therapeutics Net Debt 2011-2026 | ACER
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Acer Therapeutics
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -2.08 M | -12.3 M | -5.4 M | -11.5 M | -41.7 M | -15.6 M | -3.29 M | -12.4 M | -9.91 M | -23.6 M | -215 K | -7.11 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -215 K | -41.7 M | -12.1 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Aptorum Group Limited
APM
|
-2.77 M | $ 0.82 | -3.48 % | $ 4.47 M | ||
|
Rigel Pharmaceuticals
RIGL
|
12.5 M | $ 33.23 | -4.03 % | $ 584 M | ||
|
Graybug Vision
GRAY
|
-33.4 M | - | -11.23 % | $ 9.65 M | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-12 M | - | -11.43 % | $ 502 K | ||
|
Apellis Pharmaceuticals
APLS
|
-311 M | $ 20.15 | -2.68 % | $ 2.54 B | ||
|
AbCellera Biologics
ABCL
|
14.7 M | $ 3.72 | -2.75 % | $ 1.11 B | ||
|
Athersys
ATHX
|
-27.6 M | - | 3.77 % | $ 22.4 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
AVEO Pharmaceuticals
AVEO
|
-48 M | - | - | $ 521 M | ||
|
Axsome Therapeutics
AXSM
|
-205 M | $ 163.7 | -1.61 % | $ 8.14 B | ||
|
BridgeBio Pharma
BBIO
|
1.44 B | $ 64.66 | -1.37 % | $ 12.4 B | ||
|
Brainstorm Cell Therapeutics
BCLI
|
533 K | - | -2.5 % | $ 5.88 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 8.52 | -2.46 % | $ 1.39 B | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
CymaBay Therapeutics
CBAY
|
-206 M | - | - | $ 3.45 B | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Avid Bioservices
CDMO
|
17.5 M | - | - | $ 789 M | ||
|
Certara
CERT
|
105 M | $ 7.16 | 1.49 % | $ 1.15 B | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Checkpoint Therapeutics
CKPT
|
-40.8 M | - | - | $ 169 M | ||
|
Caladrius Biosciences
CLBS
|
-22.3 M | - | -16.75 % | $ 25.8 M | ||
|
Alpine Immune Sciences
ALPN
|
-63.9 M | - | - | $ 2.17 B | ||
|
Clovis Oncology
CLVS
|
293 M | - | -7.23 % | $ 13 M | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Checkmate Pharmaceuticals
CMPI
|
-12.1 M | - | - | $ 231 M | ||
|
Capricor Therapeutics
CAPR
|
-12.5 M | $ 25.91 | -3.56 % | $ 694 M | ||
|
Catalyst Pharmaceuticals
CPRX
|
-706 M | $ 24.0 | 0.5 % | $ 2.93 B | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Codexis
CDXS
|
12.5 M | $ 0.99 | -3.28 % | $ 72.7 M | ||
|
Corvus Pharmaceuticals
CRVS
|
-10.6 M | $ 17.75 | -0.79 % | $ 852 M | ||
|
CTI BioPharma Corp.
CTIC
|
18.3 M | - | - | $ 1.2 B | ||
|
CohBar
CWBR
|
-2.2 M | - | -15.44 % | $ 2.2 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
-3.34 M | - | -5.98 % | $ 34.1 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-3.34 M | - | -4.36 % | $ 27 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
-57.6 M | - | - | $ 2.18 B | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
Denali Therapeutics
DNLI
|
-158 M | $ 20.02 | -4.67 % | $ 3.29 B | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
Eton Pharmaceuticals
ETON
|
-10.8 M | $ 17.54 | -3.36 % | $ 450 M | ||
|
Entasis Therapeutics Holdings
ETTX
|
-55.1 M | - | - | $ 105 M | ||
|
Evofem Biosciences
EVFM
|
-475 K | - | 7.55 % | $ 38.1 M |